Literature DB >> 1606981

4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.

F C da Silva1, F Ferrito, T Brandão, A Santos.   

Abstract

The authors report the preliminary data concerning a phase III study comparing the chemoprophylactic effects of mitomycin C and epirubicin in Ta-T1 primary and recurrent superficial bladder tumors. 60 patients were treated, 32 with epirubicin and 28 with mitomycin C, with a medium follow-up of 17.7 and 16.2 months, respectively. There were no systemic side effects. The remission rate was 62.5% in the epirubicin group and 64.2% in the mitomycin C group. Both drugs were equally useful in the chemoprophylaxis of superficial bladder cancer.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1606981     DOI： 10.1159/000474798

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  8 in total

1.  Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory. Nara Uro-oncology Research Group. (NUORG).

Authors:  Y Hirao; S Ozono; H Momose; E Okajima; T Hiramatsu; K Yoshida; S Fukushima; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Authors:  Robert S Svatek; Xiang Ru Zhao; Edwin E Morales; Mithilesh K Jha; Timothy Y Tseng; Cory M Hugen; Vincent Hurez; Javier Hernandez; Tyler J Curiel
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

3.  BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.

Authors:  M D Melekos; I Zarakovitis; K Dandinis; E Fokaefs; H Chionis; H Dauaher; G Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.

Authors:  N Shinohara; K Nonomura; M Tanaka; S Nagamori; F Takakura; T Seki; T Koyanagi; M Togashi; A Maru
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Intravesical epirubicin in the prophylaxis of superficial bladder cancer.

Authors:  F Sengör; M Beysel; K Erdoğan; A Erol; D Tuzluoğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 7.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 8.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.